A-SEEDS Co., Ltd.
Development of Mass-Production Technology for the Clinical Implementation of Innovative CAR-T Cell Therapy
As of March, 2025
| City | Year of Establishment | Founder |
|---|---|---|
| Matsumoto, Nagano | 2020 | Yozo Nakazawa |
| Partner VC | Latest round of Fundraising | Valuation |
|---|---|---|
| - | Series A | Non-Disclosure |
- Contact Information: 0263-31-5882
- kiyohito.tani@a-seeds.co.jp
- Website: A-SEEDS Co., Ltd.
Program name
Deep-Tech Startups Support Program
Business Plan
A-SEEDS, an innovative biotech company sprouted from Shinshu University, is dedicated to pioneering advanced treatments for life-threatening cancers. Harnessing the potential of non-viral genetic engineering, our cutting-edge immune cell therapy opens up new horizons of hope for patients seeking effective and transformative solutions.
Research Outline
The objective of this project is to develop large-scale manufacturing technology for CAR-T cell therapy, a novel approach to cancer treatment, utilizing non-viral gene editing methods. Additionally, we aim to establish a robust manufacturing infrastructure through collaboration with domestic and international formulation development and manufacturing support companies, with a view toward conducting global clinical trials and obtaining regulatory approval, while also validating the technology internationally.
| Phase | Business Area/Field | Research Period | Research Grant Amount |
|---|---|---|---|
| PCA | Healthcare | 2025-2026FY | JPY 920 million |
International collaborative technology demonstration
| Countries/Regions | Collaborative activity outline |
|---|---|
| Australia |
|
Last Updated : August 13, 2025